Associate Director, Biostatistics Consultant – Oncology (Remote in Western EU)

<p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Are you interested in working directly for a single sponsor while having the security and additional career opportunities that working for a global CRO can bring? Our team says it’s the best of both worlds….</span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">ClinChoice is searching for a <strong>Associate Director, Biostatistics Consultant &nbsp;– Oncology</strong> <strong>&nbsp;</strong>to join one of our clients.&nbsp;</span></p> <h2 style="line-height: 1.2;" data-pm-slice="1 1 []"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Position Summary</span></h2> <p style="line-height: 1.2;" data-pm-slice="1 3 []"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">We are seeking an experienced <strong>Associate Director, Biostatistics</strong> with strong expertise in <strong>oncology drug development and clinical trial strategy</strong>. The individual will provide strategic statistical leadership across development programs and work closely with Clinical Development, Regulatory, Medical, Commercial, and Portfolio teams.</span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">The ideal candidate should have experience in:</span></p> <ul> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Selecting Trial Types: decide if a trial should be superiority, non-inferiority, or equivalence-based depending on what regulators and payers need to prove the drug beats a placebo or standard of care.</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Endpoint Selection: define and validate primary and secondary endpoints (e.g., overall survival, biomarker response rates, quality-of-life scores) to ensure they are measurable, clinically meaningful, and statistically robust.</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Innovative Designs: statisticians frequently design <strong>adaptive trials</strong> (e.g., seamless Phase II/III designs, group sequential designs, or biomarker-driven basket/umbrella trials) to save time and patients.</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Sample Size &amp; Power Calculations</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Balancing Risk and Resources: &nbsp;use power calculations to ensure a trial has a high probability of detecting a true clinical effect without enrolling excess patients, which drives up costs and exposes unnecessary individuals to experimental risks.</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Subgroup Powering: They determine if the study is large enough to analyze specific patient subsets (e.g., biomarker-positive patients or specific age groups).</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Establishing <strong>Go/No-Go Decision Gates</strong></span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Proof-of-Concept Criteria: establish quantitative thresholds for Phase II trials (e.g., "If the hazard ratio is below 0.70 with a p-value , we proceed to Phase III").</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Futility Stopping Rules: Experience in build rules into trial protocols to stop a failing trial early, preventing sunk costs on a drug that is unlikely to succeed.</span></li> </ul> <ul> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Regulatory Strategy and Health Authority Negotiations : experience in preparing and reviewing data packages and attending meetings with regulatory bodies (like the FDA or EMA) to defend trial designs, proposed endpoints, and statistical analysis plans (SAPs).</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Mitigating Regulatory Risk: Experience in anticipating and addressing statistical objections from health authorities regarding missing data handling, multiplicity adjustments (controlling for false positives when looking at multiple endpoints), and bias.</span></li> </ul> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">At the macro–Strategic Drug Development level, statisticians should have experience working with <strong>commercial and portfolio management teams</strong>.</span></p> <ul> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Quantifying Uncertainty: Experience in using historical benchmark data and simulation models to estimate the Probability of Technical Success (PoS) for an asset at each development phase.</span></li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Pipeline Prioritization: Using risk models to help executive leadership in deciding whether to advance, partner, or kill an asset based on its statistical likelihood of clearing regulatory and market hurdles.</span></li> </ul> <h2 style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Qualifications</span></h2> <ul data-spread="false"> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Master's or Ph.D. in Statistics, Biostatistics, or a related quantitative discipline.</span></p> </li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Significant experience in pharmaceutical, biotechnology, or CRO environments with strong <strong>oncology experience</strong>.</span></p> </li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Demonstrated experience in <strong>strategic drug development and clinical trial design</strong>, beyond traditional study-level responsibilities.</span></p> </li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Strong knowledge of oncology endpoints, adaptive designs, sample size/power, simulations, and statistical methodology.</span></p> </li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Experience supporting <strong>regulatory submissions and health authority interactions</strong>.</span></p> </li> <li style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"> <p><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Excellent communication and leadership skills with the ability to influence senior cross-functional stakeholders.</span></p> </li> </ul> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Application Process</strong></span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Once you have submitted your CV, you will receive an acknowledgement that we received it. If you have the requirements we need, you will be invited for phone interview as the first step.&nbsp; Unfortunately, due to the number of applications we receive, we cannot reply to everyone individually if you are not successful.</span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Who will you be working for?</strong></span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><strong>About ClinChoice</strong></span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">ClinChoice is a global full-service CRO specializing in clinical development and functional solutions for pharmaceutical, biotechnology, medical device, and consumer health companies. We have over 28 years of proven high-quality delivery and results across all our services, with over 4,000 professionals in more than 20 countries across the Americas, Europe, and Asia-Pacific.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Our Company Ethos</strong></span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">Our mission drives our culture: to contribute to a healthier and safer world by accelerating the development and commercialization of innovative drugs and devices. Our employees are the most valuable company asset and they are the fulcrum around which all ClinChoice activities are built and close management and training is the core instrument to develop and maintain highly-qualified personnel. The continuous training keeps the resources qualified in terms of competence and expertise and gives all personnel the clear tools needed to manage both internal and client processes with the same methodology.&nbsp;&nbsp; The success of these core values is evidenced by our below industry average turnover rates.</span></p> <p style="line-height: 1.2;"><span style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;">ClinChoice is an equal opportunity employer. We have based our success on attracting, developing, and promoting talent guided by diversity and inclusivity. Our employees come from very diverse backgrounds: gender, race, beliefs, and ethnicities. We recognize this is our strength and celebrate it.</span></p> <p style="line-height: 1.2;"><span class="ui-provider a b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak" style="font-family: tahoma, arial, helvetica, sans-serif; font-size: 12pt;"><strong><br><span data-teams="true">#LI-TT1 #LI-Remote #Associate Director #contract</span></strong></span></p> <h2 style="line-height: 1.2;" data-pm-slice="1 3 []">&nbsp;</h2> <p>&nbsp;</p>